From banking to biotech – Renée Aguiar-Lucander’s unique path in science

BPR: Could you give us an overview of your work?

I joined Calliditas Therapeutics as CEO in 2017, and in this role I have led the company from a small team of just 10 people to an international biopharmaceutical company with over 200 employees. Calliditas is now a successful commercial-stage biopharma company with a pipeline of late stage novel medications to address a range of orphan indications, with an initial focus on renal diseases.

During my time as CEO of Calliditas, one of our most significant achievements came in 2023. Our lead asset, TARPEYO, received full approval from the FDA for the treatment of IgA Nephropathy (IgAN). This approval marked a historic milestone as TARPEYO became the first FDA-approved therapy for this disease with a view to significantly reduce the loss of kidney function in IgAN patients.

As the CEO, my role is focused on building highly experienced and motivated teams, moving the company towards its strategic goals, ensuring effective communication within the team, and working closely with various stakeholders to optimize performance.

BPR: When did you realize you were interested in science – as a young child, teen, or older?

I actually found science to be intimidating and frustrating in my teens, however as I started to work with talented operators and investors in life sciences, which continued over many decades, I developed my own interpretation of science and enjoyed its many facets and challenges.  So, while I didn’t initially envision a career in science, my experiences in analyzing, supporting, investing in and ultimately building and running a life science business has given me an appreciation for what is required to make a meaningful impact within a scientific context.

Leave a Reply

Your email address will not be published. Required fields are marked *